Signal US federal drug agency funds non-hallucinogenic psychedelic development with $11.4 million
Summary
The Initiative reports that AtaiBeckley received up to 11.4 million dollars in non-dilutive NIH and NIDA funding to develop non-hallucinogenic 5-HT2A/2C agonists for opioid use disorder. GWI treats the grant as federal validation of the neuroplastogen approach.
Classification
Main topicBio & Health Tech
Region menusNorth America
Occurrencescope:country · geo_region:north_america · country:US
Impactscope:country · geo_region:north_america · country:US
Time horizon0-3 years (2026-07-26)
Last updated2026-07-29 04:49:53
Evidence 1
- Initiative Trends 2026: Collective Intelligence and Foresight from Global Wellness Leaders Global Wellness Institute page=83;section=Psychedelics and Healing Initiative Trends / TREND 2: Neuroplastogens - The Quiet Redefinition of Psychedelic Medicine 2026-05 accessed 2026-07-26
Part of trends 1
Directly linked issues 0
No objects.
Relation types: supports
Public id: fm-911091b94591